Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist
7 months, 3 weeks ago

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist

News 18  

Only seven to eight individuals out of 10 lakh, who receive the coronavirus vaccine Covishield, face the risk of experiencing a rare side effect known as thrombosis thrombocytopenia syndrome. India’s top epidemiologist, former ICMR scientist Dr Raman Gangakhedkar, said those who got this vaccine have “no risk at all”. Gangakhedkar, who is known for his simplistic approach to clearing complicated matters, said: “Such a rare chance of damage exists even when you drive on the road or even when an individual chooses to complete a course of medication or take a vitamin shot.” He further said: “When an individual is prescribed a course of a vitamin B12 injection, they are being asked to take the first shot in the hospital due to chances of an anaphylaxis reaction.” Anaphylaxis is a severe and life-threatening reaction, which can happen seconds or minutes after the person has been exposed to something they are allergic to. “Hence, we can’t estimate the benefit of the Covishield vaccine, which comprises more than 90 per cent of Covid-19 vaccination among the Indian population,” Gangakhedkar said.

Indian Risk Vaccine Icmr 10 Lakh Covishield Tts Effect Known Gangakhedkar  effect  known  rare  risk  scientist  lakh  covishield  indian  icmr  vaccine  face  covid19  clotting  tts  gangakhedkar

History of this topic

AstraZeneca's Covid vaccine linked to another rare blood disorder
7 months, 1 week ago

AstraZeneca's Covid vaccine linked to another rare blood disorder

India Today  

Over a week after AstraZeneca announced a global withdrawal of its vaccine against coronavirus citing a slowdown in sales and availability of enough options in the market, new research has linked it to a rare disorder. Researchers found that the AstraZeneca vaccine, sold in India under the brand name Covishield, is linked to a rare blood clotting disorder called Vaccine-Induced …

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines
7 months, 1 week ago

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines

News 18  

In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine manufactured by the Serum Institute of India. At a press conference, the doctors, under the banner of the Awaken India Movement, …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots
7 months, 2 weeks ago

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots

The Independent  

The best of Voices delivered to your inbox every week - from controversial columns to expert analysis Sign up for our free weekly Voices newsletter for expert opinion and columns Sign up to our free weekly Voices newsletter Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, …

Stopped manufacturing Covishield since December 2021, says Serum Institute
7 months, 2 weeks ago

Stopped manufacturing Covishield since December 2021, says Serum Institute

Hindustan Times  

Pune-based Serum Institute of India stopped manufacturing its anti-Covid-19 vaccine Covishield in 2021, according to a statement issued by the company on Wednesday after British-Swedish pharmaceutical manufacturer AstraZeneca announced it was withdrawing its vaccine against Covid, Vaxzevria, due to “commercial reasons” as demand for it decreased globally. Consequently, since December 2021, we have stopped the manufacturing and supply of additional …

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors
7 months, 2 weeks ago

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors

The Hindu  

At a time when the safety aspects of the Covishield vaccine have kicked up a row, a retrospective study by two doctors from Kozhikode has claimed that its risks are minimal in view of the benefits. The controversy arose after pharmaceutical company AstraZeneca admitted in the High Court of London, United Kingdom, that its vaccine against COVID-19 had the potential …

Covishield: Gujarat Cong Demands Compensation, BJP Claims Heart Attacks Not Linked to Vaccine
7 months, 3 weeks ago

Covishield: Gujarat Cong Demands Compensation, BJP Claims Heart Attacks Not Linked to Vaccine

News 18  

The opposition Congress on Wednesday alleged that the BJP government at the centre did not follow the guidelines of the World Health Organisation, and demanded that the relatives of those who died due to heart attack or similar reasons after taking the Covishield vaccine against coronavirus should be paid compensation. Doctors associated with the Gujarat BJP, however, said a study …

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’
7 months, 3 weeks ago

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

The Hindu  

The controversy over the safety aspects of the Covishield vaccine reached the Supreme Court on Wednesday, May 1, 2024, with a petition seeking the constitution of an expert medical panel to study the risk factors. Now after the document filed in UK court by the developer of Covishield, we are compelled to think on the risk and hazardous consequences of …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

AstraZeneca’s submission in U.K. court nothing new, say doctors over Covishield’s potential to cause blood clots
7 months, 3 weeks ago

AstraZeneca’s submission in U.K. court nothing new, say doctors over Covishield’s potential to cause blood clots

The Hindu  

Following pharmaceutical company AstraZeneca’s admission in U.K. court documents that its vaccine against COVID-19 has the potential to cause Thrombosis with Thrombocytopenia Syndrome, a rare side effect associated with blood clotting, doctors in India said this is not new information and that they are “well aware of the warning which has been available in India as an insert with the …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

Global study quantifies rise in blood clots, heart inflammation following COVID-19 vaccination
10 months ago

Global study quantifies rise in blood clots, heart inflammation following COVID-19 vaccination

The Hindu  

One of the largest assessments of its kind, spanning 99 million people and investigating reports of adverse reactions following COVID-19 vaccination, found that instances of Guillain Barre Syndrome, myocarditis, pericarditis and cerebral venous sinus thrombosis were at least 1.5 times more than expected following inoculation with mRNA and ChadOX1 vaccines. The Global Covid Vaccine Safety Project, which made the assessment, …

At 14,493, India records sharp dip in daily Covid tally, logs 801 new cases
1 year, 7 months ago

At 14,493, India records sharp dip in daily Covid tally, logs 801 new cases

Hindustan Times  

India has logged 801 new coronavirus infections, while the active cases have dipped to 14,493 from 15,515, according to the Union Health Ministry data updated on Monday. According to the ministry's website, 220.66 crore doses of Covid vaccine have been administered in the country so far under the nationwide vaccination drive. The active cases now comprise 0.03 per cent of …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

No second Covid-19 booster dose required: Report
1 year, 11 months ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla
2 years ago

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla

The Hindu  

Serum Institute of India CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent. Mr. Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of …

AstraZeneca Covid Jab Linked to 30% Higher Risk of Very Rare Blood Clot: Study
2 years, 1 month ago

AstraZeneca Covid Jab Linked to 30% Higher Risk of Very Rare Blood Clot: Study

News 18  

AstraZeneca’s Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said Thursday. Several countries have already altered their advice after previous research indicated that — in a tiny number of cases — thrombosis with thrombocytopenia syndrome can be a possible side effect …

COVID-19: Corbevax to be given as boosters at vaccination centres from today
2 years, 4 months ago

COVID-19: Corbevax to be given as boosters at vaccination centres from today

Live Mint  

Hyderabad based-Biological E Ltd 's recently approved heterologous Covid-19 vaccine Corbevax to be available as a booster dose on the COWIN App in both public and private vaccination centres from 12 August, the firm said on 11 August. The Union Health Ministry approved Corbevax as India's first heterologous COVID-19 booster shot for 18 years and above after the six months …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre
2 years, 5 months ago

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre

Firstpost  

Minister of State for Health Bharati Pravin Pawar said as on 19 July, 2022, a total of 200.34 crore COVID-19 vaccine doses have been administered to beneficiaries above 12 years of age in the country New Delhi: India has supplied 23.9 crore doses of coronavirus vaccine to 101 countries and UN entities in the form of grant, commercial export, or …

India reports 45 covid deaths, over 21,000 fresh cases in a day
2 years, 5 months ago

India reports 45 covid deaths, over 21,000 fresh cases in a day

Live Mint  

New Delhi: India reported 45 covid-19 deaths and 21,566 new cases in the last 24 hours, the union health ministry data stated on Thursday. The central government reviewed covid-19 situation in 115 districts of nine states showing an upsurge in cases and positivity rate, and flagged concerns regarding low levels of testing and vaccination. States were directed to report and …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

Free Covid booster doses will create healthier country: PM Modi
2 years, 5 months ago

Free Covid booster doses will create healthier country: PM Modi

India Today  

Prime Minister Narendra Modi on Wednesday said the government's decision to administer free precautionary doses of Covid-19 vaccines to all citizens aged above 18 will further India's vaccination coverage and create a healthier country. As part of 'Azadi Ka Amrit Mahotsav' celebrations, free precautionary doses of Covid-19 vaccines will be administered to all citizens above the age of 18 at …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study
2 years, 5 months ago

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study

The Hindu  

COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic. In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide, according to …

COVID waves to come in every four to six months, booster shots important, says WHO's chief scientist
2 years, 6 months ago

COVID waves to come in every four to six months, booster shots important, says WHO's chief scientist

Firstpost  

Emphasising on importance of booster shots, Soumya Swaminathanthe, former Indian Council of Medical Research chief, said that boosters are important to boost waning immunity, especially for vulnerable people Booster shots are important as countries are likely to see waves of Covid-19 infection every four to six months, World Health Organization’s chief scientist Soumya Swaminathan told News18.com. Emphasising the importance of …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 6 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Corbevax: India's First Protein Sub-Unit Covid Vaccine Recommended for Emergency Use in 5-12 Year Olds
2 years, 8 months ago

Corbevax: India's First Protein Sub-Unit Covid Vaccine Recommended for Emergency Use in 5-12 Year Olds

News 18  

As India battles a fresh surge in coronavirus cases, the Subject Expect Committee of the Drug Controller General of India on Thursday recommended emergency use of Biological E.’s Corbevax in children in the age group of 5-12 years. Corbevax, developed by the Hyderabad-based Biological E. Ltd in collaboration with the Texas Children’s Hospital Centre for Vaccine Development and Baylor College …

India approves ‘precaution’ doses of COVID-19 vaccine for all over 18 from April 10
2 years, 8 months ago

India approves ‘precaution’ doses of COVID-19 vaccine for all over 18 from April 10

The Hindu  

The Union Health Ministry on Friday announced that the precautionary or third dose of COVID-19 vaccine would be made available to the 18+ population at private vaccination centres. 1,109 new infections The decision comes even as India logged 1,109 new coronavirus infections taking the total tally of COVID-19 cases to 4,30,33,067,while the active cases dipped to 11,492, according to the …

Serum Institute's Covishield precaution dose priced at Rs 600 per shot
2 years, 8 months ago

Serum Institute's Covishield precaution dose priced at Rs 600 per shot

India TV News  

Highlights SII said precaution dose of its Covishield vaccine against COVID will be priced at Rs 600 per shot Hospitals will get at discounted price More than 2.4 crore precaution doses have also been administered Vaccine maker Serum Institute of India on Friday said the precaution dose of its Covishield vaccine against COVID-19 will be priced at Rs 600 per …

India's drugs regulator approves phase-3 trial of covid vaccine covovax
2 years, 9 months ago

India's drugs regulator approves phase-3 trial of covid vaccine covovax

India Today  

The Drugs Controller General of India granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults, official sources said. The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose …

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield
2 years, 9 months ago

Why India's vaccine advisory body recommends reducing second-dose gap for Covishield

Firstpost  

The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to eight to 16 weeks, from the current gap of 12 to 16 The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to …

Coronavirus updates March 04, 2022
2 years, 9 months ago

Coronavirus updates March 04, 2022

The Hindu  

In 2022, 92% of COVID deaths have been in unvaccinated individuals, Director General of the Indian Council of Medical Research Dr. Balram Bhargava said on Thursday. Here are the latest updates Study Third Covid vaccine dose advised for immunocompromised people: study A third dose of the COVID-19 vaccine is recommended for people with a weakened immune system, especially for organ …

Very small blood clot risk after first AstraZeneca Covid shot, say UK studies
2 years, 10 months ago

Very small blood clot risk after first AstraZeneca Covid shot, say UK studies

India Today  

A large study into rare blood clots linked with AstraZeneca's Covid-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side-effects from the shot. Read: BA.2 sub-variant of Omicron spreads faster, but not more severe, says WHO A study published in the PLOS Medicine journal on Tuesday looked …

Corbevax COVID vaccine is safe, offers high antibody levels: NTAGI chief
2 years, 10 months ago

Corbevax COVID vaccine is safe, offers high antibody levels: NTAGI chief

Deccan Chronicle  

New Delhi: India's third homegrown COVID-19 vaccine Corbevax is safe and offers good immunogenicity and higher antibody levels than some other vector vaccines, said Dr N K Arora, Chairman, India's COVID-19 Working group of National Technical Advisory Group on immunisation. The NTAGI chief's remarks came after the Drugs Controller General of India's Subject Expert Committee recommended Emergency Use Authorization to …

Covishield, Covaxin get sale approval in India
2 years, 10 months ago

Covishield, Covaxin get sale approval in India

Deccan Chronicle  

New Delhi: The Drugs Controller-General of India on Thursday granted regular market approval for the Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin for use in the adult population subject to conditions. As Covid-19 infections, driven by the Omicron variant, are still raging, with 407 districts reporting a positivity rate of over 10 per cent, the Centre on Thursday …

Covishield, Covaxin get conditional market nod
2 years, 10 months ago

Covishield, Covaxin get conditional market nod

Hindustan Times  

The Drugs Controller General of India, India’s pharmaceuticals regulator, granted a conditional market authorisation for Covishield and Covaxin, the two coronavirus vaccines widely used in the country, officials said on Thursday. “The @CDSCO_INDIA_INF has now upgraded the permission for Covaxin and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions,” …

COVID-19 fatalities low in TN compared to other states: Health minister
2 years, 11 months ago

COVID-19 fatalities low in TN compared to other states: Health minister

Deccan Chronicle  

Chennai: The number of fatalities caused due to COVID-19 in Tamil Nadu was 'less' as compared to other states because 65 per cent of the population has two doses of vaccination, Tamil Nadu Minister Ma Subramanian said on Saturday. Underlining the need to get inoculated to safeguard oneself from the virus, Subramanian said 89 per cent of the people have …

Panel pitches full market nod for Covaxin, Covishield
2 years, 11 months ago

Panel pitches full market nod for Covaxin, Covishield

Hindustan Times  

The subject expert panel of the national drugs regulator on Wednesday recommended full market authorisation for both Covaxin and Covishield under certain conditions, according to people familiar with the developments. Serum Institute of India and Bharat Biotech International Ltd, manufacturers of Covishield and Covaxin respectively, separately applied to the central drugs standard control organisation to seek full market authorisation stating …

SEC recommends Covaxin, Covishield for full market authorisation: Report
2 years, 11 months ago

SEC recommends Covaxin, Covishield for full market authorisation: Report

Hindustan Times  

The subject expert committee of the Central Drugs Standard Control Organisation on Wednesday recommended regular market approval for Covaxin and Covishield, the two most widely used jabs in the national vaccination drive against Covid-19, news agency PTI has reported, citing official sources. The development comes just days after the SEC, on January 14, sought more data from the two manufacturers--Hyderabad-based …

India reports 2.58 lakh COVID-19 cases in 24 hours; positivity rate rises from 16.28% to 19.65%
2 years, 11 months ago

India reports 2.58 lakh COVID-19 cases in 24 hours; positivity rate rises from 16.28% to 19.65%

Firstpost  

Active coronavirus cases now stand at 16,56,341, while the recovery rate is 94.27 per cent; the Omicron tally has increased to 8,209 India reported 2.58 lakh cases — around five per cent lower than yesterday — and 385 fatalities in the last 24 hours, according to the health ministry. The country’s Omicron tally stands at 8,209 Active cases now comprise …

Discover Related